RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, has received a Phase I SBIR grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). The SBIR grant, in the amount of $100,000, will be used to support the development of biomimetic compounds as anticoagulant antagonists.
